Reunion Neuroscience upsizes Series A to $133 million after positive trial data

Reunion Neuroscience Inc. (Private) — Reunion Neuroscience announced the final closing of its Series A, with the last tranche increasing from $21 million to $51 million to bring the round to $133 million.

The upsize was triggered after its RECONNECT study of RE104 in postpartum depression met pre-set efficacy criteria. Proceeds fund the ongoing REKINDLE Phase 2 trial in adjustment disorder and expansion of RE104 into generalized anxiety disorder.

Source: globenewswire.com

For the rest of that week's sector news, read our week in review.